Complementation of two mutant p53: Implications for loss of heterozygosity in cancer

被引:8
作者
Demidenko, ZN
Fojo, T
Blagosklonny, MV
机构
[1] New York Med Coll, Brander Canc Res Inst, Valhalla, NY 10595 USA
[2] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
cancer; p53; tumor suppressor;
D O I
10.1016/j.febslet.2005.03.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Remarkably, a cancer cell rarely possesses two mutant p53 proteins. Instead, mutation of one allele is usually associated with loss of the second p53 allele. Why do not two mutant p53 co-exist? We hypothesize that two different p53 may complement each other, when expressed at equal levels. By titrating trans-deficient and DNA-binding-deficient p53 in cells with mutant p53 and by co-transfecting distinct mutant p53 in p53-null cells, we demonstrated activation of p53-dependent transcription. We suggest that, due to complementation of two mutant p53, cancer cells need to delete the second p53 allele rather than mutate it. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.Ni. All rights reserved.
引用
收藏
页码:2231 / 2235
页数:5
相关论文
共 43 条
[1]  
BAKER SJ, 1990, CANCER RES, V50, P7717
[2]   p53 inhibits hypoxia-inducible factor-stimulated transcription [J].
Blagosklonny, MV ;
An, WG ;
Romanova, LY ;
Trepel, J ;
Fojo, T ;
Neckers, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :11995-11998
[3]   p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect [J].
Blagosklonny, MV .
FASEB JOURNAL, 2000, 14 (13) :1901-1907
[4]  
Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO
[5]  
2-6
[6]   Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death? [J].
Blagosklonny, MV .
BIOESSAYS, 2001, 23 (10) :947-953
[7]   Inhibition of HIF-1-and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions [J].
Blagosklonny, MV ;
Giannakakou, P ;
Romanova, LY ;
Ryan, KM ;
Vousden, KH ;
Fojo, T .
CARCINOGENESIS, 2001, 22 (06) :861-867
[8]  
BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933
[9]   Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[10]  
Brooks CL, 2004, CELL CYCLE, V3, P895